Additional Information

Description

Granix (tbo-filgrastim) 480 mcg/0.8 mL is a granulocyte colony-stimulating factor (G-CSF) used to reduce the duration of neutropenia in patients undergoing myelosuppressive chemotherapy. It stimulates the production, maturation, and activation of neutrophils, enhancing the body's ability to fight infections. By binding to specific cell surface receptors, Granix promotes proliferation and differentiation of neutrophil precursors, leading to increased neutrophil counts in circulation.

The drug is supplied as a prefilled syringe containing 480 mcg of tbo-filgrastim in 0.8 mL of solution. It is administered via subcutaneous injection, with dosing based on patient weight and chemotherapy regimen. Injection timing is crucial, typically starting 24 hours after chemotherapy completion to avoid overstimulation of bone marrow precursors.

Common adverse effects include bone pain, injection site reactions, headache, and fatigue. More serious reactions, such as splenic rupture, acute respiratory distress syndrome (ARDS), and severe allergic responses, may occur but are rare. Patients receiving Granix require monitoring for excessive leukocytosis and signs of hypersensitivity.